- Home
- PLUR vs ACRV Comparison
PLUR vs ACRV Comparison
Compare PLUR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- ACRV
- Stock Information
- Founded
- PLUR 2001
- ACRV 2018
- Country
- PLUR Israel
- ACRV United States
- Employees
- PLUR N/A
- ACRV N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- PLUR Health Care
- ACRV Health Care
- Exchange
- PLUR Nasdaq
- ACRV Nasdaq
- Market Cap
- PLUR 41.9M
- ACRV 40.4M
- IPO Year
- PLUR N/A
- ACRV 2022
- Fundamental
- Price
- PLUR $5.08
- ACRV $1.34
- Analyst Decision
- PLUR Strong Buy
- ACRV Buy
- Analyst Count
- PLUR 1
- ACRV 7
- Target Price
- PLUR $12.00
- ACRV $17.60
- AVG Volume (30 Days)
- PLUR 64.6K
- ACRV 366.8K
- Earning Date
- PLUR 05-13-2025
- ACRV 08-12-2025
- Dividend Yield
- PLUR N/A
- ACRV N/A
- EPS Growth
- PLUR N/A
- ACRV N/A
- EPS
- PLUR N/A
- ACRV N/A
- Revenue
- PLUR $1,034,000.00
- ACRV N/A
- Revenue This Year
- PLUR $472.39
- ACRV N/A
- Revenue Next Year
- PLUR $254.29
- ACRV N/A
- P/E Ratio
- PLUR N/A
- ACRV N/A
- Revenue Growth
- PLUR 203.23
- ACRV N/A
- 52 Week Low
- PLUR $3.33
- ACRV $1.05
- 52 Week High
- PLUR $7.13
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- PLUR 53.31
- ACRV 56.41
- Support Level
- PLUR $4.57
- ACRV $1.23
- Resistance Level
- PLUR $5.52
- ACRV $1.40
- Average True Range (ATR)
- PLUR 0.39
- ACRV 0.08
- MACD
- PLUR -0.02
- ACRV 0.01
- Stochastic Oscillator
- PLUR 47.27
- ACRV 84.04
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.